A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

Schizophrenia, Schizoaffective Disorder Clinical Trial

Official title:
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of RO6889450 (Ralmitaront) in Patients With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

Status Terminated

Clinical Trial Summary

This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Psychotic Disorders
Schizophrenia
Schizophrenia, Schizoaffective Disorder

Clinical Trial Details

NCT number	NCT03669640
Study type	Interventional
Source	Hoffmann-La Roche
Contact
Status	Terminated
Phase	Phase 2
Start date	December 4, 2018
Completion date	May 8, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04512066` - A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder	Phase 2
Completed	`NCT02192593` - Computerized Cognitive-Behavioral Therapy for Auditory Hallucinations	N/A
Completed	`NCT00224315` - Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial	Phase 4
Recruiting	`NCT02808533` - Topiramate and Schizophrenia: Effects on Weight and Psychopathology	N/A
Recruiting	`NCT06319170` - Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder	Phase 1